DeepMed Research

EISAI INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: E2609
Drug: Placebo for E2609

First Posted Date: 2012-05-17

Last Posted Date: 2016-12-30

Lead Sponsor: Eisai Inc.

Target Recruit Count: 65

Registration Number: NCT01600859

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Phase 1

Completed

Conditions: Idiopathic Thrombocytopenic Purpura

Interventions: Drug: 10-mg dose of E5501 cyclodextrin oral solution
Drug: 10-mg dose of E5501 lipid-based oral
Drug: 10-mg dose of E5501 2G tablet
Drug: 10-mg dose of E5501-P21% powder

First Posted Date: 2012-03-08

Last Posted Date: 2013-11-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 28

Registration Number: NCT01549054

Locations: 🇬🇧
Quotient, Nottingham, United Kingdom

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Lenvatinib
Drug: Lenvatinib matched placebo
Drug: BSC

First Posted Date: 2012-02-08

Last Posted Date: 2017-09-26

Lead Sponsor: Eisai Inc.

Target Recruit Count: 135

Registration Number: NCT01529112

Locations: 🇧🇪
C. H. R. de la Citadelle, Liege, Belgium
🇭🇺
Tudogyogyintezet Torokbalint, Torokbalint, Hungary
🇭🇺
Fejer Megyei Szent Gyorgy Korhaz, Szekesfehervar, Hungary

and more 47 locations

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Phase 2

Completed

Conditions: Central Nervous System

Interventions: Drug: perampanel

First Posted Date: 2012-02-06

Last Posted Date: 2016-07-12

Lead Sponsor: Eisai Inc.

Target Recruit Count: 63

Registration Number: NCT01527006

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Phase 1

Completed

Conditions: Lymphomas
Refractory Solid Tumors

Interventions: Drug: Moxifloxacin 400 mg
Drug: Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
Drug: Lenvatinib

First Posted Date: 2012-02-02

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 52

Registration Number: NCT01525394

Locations: 🇺🇸
Charles River, Tacoma, Washington, United States

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: E2609
Drug: Placebo

First Posted Date: 2012-01-19

Last Posted Date: 2015-11-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 50

Registration Number: NCT01511783

Locations: 🇺🇸
Compass Research Phase 1, LLC, Orlando, Florida, United States

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: E2006 1.0 mg
Drug: E2006 2.5 mg
Drug: E2006 5.0 mg
Drug: E2006 10.0 mg
Drug: E2006 25.0 mg
Drug: E2006 50.0 mg
Drug: E2006 100 mg
Drug: Zolpidem 10 mg
Drug: E2006 Matched Placebo or Zolpidem Matched Placebo
Drug: E2006 Matched Placebo
Drug: E2006 200 mg

First Posted Date: 2011-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Eisai Inc.

Target Recruit Count: 122

Registration Number: NCT01463098

Locations: 🇺🇸
Community Research, Cincinnati, Ohio, United States
🇺🇸
Clinilabs, Inc., New York, New York, United States

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
Drug: Eribulin

First Posted Date: 2011-10-19

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 540

Registration Number: NCT01454934

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Positive Tumor
Breast Cancer

Interventions: Drug: eribulin mesylate
Drug: capecitabine

First Posted Date: 2011-09-23

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 77

Registration Number: NCT01439282

Locations: 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸
Arizona Oncology Associates, PC - CASA, Tucson, Arizona, United States
🇺🇸
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center, Bronx, New York, United States

and more 20 locations

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Phase 3

Completed

Conditions: Chronic Thrombocytopenia
Immune Thrombocytopenia

Interventions: Drug: Placebo
Drug: Avatrombopag
Drug: Standard of care

First Posted Date: 2011-09-22

Last Posted Date: 2018-02-05

Lead Sponsor: Eisai Inc.

Target Recruit Count: 49

Registration Number: NCT01438840

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy